Valneva Shares Drop 6.38% Midday Monday
Valneva's stock fell by 6.38% to 4.106 euros on Monday, January 26, at midday, amidst the backdrop of the voluntary withdrawal announced on January 19 of the authorization applications for the IXCHIQ vaccine in the United States. Analysts remain divided, with price targets ranging from 3.25 euros (Goldman Sachs) to 10 euros (Stifel), with focus now shifting to the Lyme disease vaccine being developed with Pfizer.
Midday Market Movements
Valneva's stock experienced a midday downturn of 6.38%, bringing its price down to 4.106 euros. This decline follows a particularly turbulent stock performance since the announcement on the evening of Sunday, January 19, of the voluntary withdrawal of authorization applications for the chikungunya vaccine IXCHIQ in the United States. The Nantes-based laboratory made this decision following the FDA's license suspension in August 2025 and a new serious adverse event reported abroad. Despite this challenging context, the stock managed to rebound on Thursday, January 22, closing with a rise of 3.93%, before losing ground again this Monday. Technically, the RSI stands at 59, in a neutral zone and away from oversold or overbought thresholds, indicating no short-term excess signal. The MACD, with a line at 0.14 slightly below its signal line at 0.15 and a negative histogram at -0.01, confirms a weakening of the bullish momentum and suggests a possible continuation of the bearish movement in the short term. However, the price remains above its 50-day moving average set at 3.92 euros, preserving a still bullish medium-term trend. The resistance at 4.43 euros remains a key technical obstacle, while the support at 3.49 euros is a floor to watch in case of further decline.
Analyst Recommendations Remain Mixed
Analyst recommendations for Valneva are highly contrasted, reflecting the uncertainties surrounding the commercial future of IXCHIQ and the prospects of the pipeline. Stifel recently raised its price target from 9.50 to 10 euros on January 6, 2026, while maintaining a buy recommendation, betting on the potential of the Lyme disease vaccine co-developed with Pfizer, whose authorization application is expected in 2026. Conversely, Goldman Sachs maintains a neutral stance with a lowered target to 3.25 euros at the end of November 2025, indicating a potential downside of 21% from the current price, reflecting a cautious view on the group's ability to offset the loss of the American market for IXCHIQ. Fundamentally, Valneva reported a revenue of 127 million euros for the first nine months of 2025, an increase of 8.9% year-on-year, with an adjusted negative EBITDA of 37.7 million euros. The group expects annual sales to range between 165 and 180 million euros for 2025. Investors' attention is now turning to the development of the VLA15 vaccine against Lyme disease, whose Phase 3 VALOR results could be a major catalyst in 2026, as well as the group's ability to offset potential revenue losses in the United States for IXCHIQ with sustained growth in Europe, Brazil, and resource-limited countries.
